At 37 years old, with a thriving concrete business, a wife and three young children, dying was the last thing on Travis Roberts’ mind. But after a doctor’s visit for a kidney stone, Roberts learned he had cholangiocarcinoma, a cancer of the bile duct. His survival rate was zero.
Roberts shared his story as part of Northwestern Mutual’s ongoing Client Stories series, which highlights the importance of financial security in the face of life’s most difficult circumstances.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7100753-northwestern-mutual-financial-security-cancer-diagnosis-disability-insurance/
The bayou is home to Ghostwalker Wyatt Fontenot whose powers are both deadly and necessary for his survival as part of an elite and secret para military team. But when his home and family are threatened, Wyatt becomes the most dangerous thing in the bayou. At least until a sensual and mysterious woman called Pepper enters his life, needing him in more ways then either of them were prepared for. From #1 NY Times bestselling author Christine Feehan. Find out more at http://www.ChristineFeehan.com. Paranormal romance/fantasy/thriller
Results from a large retrospective data analysis published in the American Journal of Transplantation (AJT) today, showed that liver transplantation patients who were treated early with Advagraf experienced a significantly increased graft survival benefit of 8% at 3 years post-transplant compared with patients treated with the current standard of care, tacrolimus immediate release (twice daily).
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7451251-advagraf-prolonged-release-tacrolimus/
Eagle Rare Kentucky Straight Bourbon Whiskey has named Alana Miller of St. Pauls, North Carolina, as the winner of the Grand Prize 2015 Rare Life Award. Eagle Rare will donate $50,000 to Miller’s charity, Blind Cat Rescue & Sanctuary, and host an awards ceremony in St. Pauls on March 14.
The Rare Life Award is an annual recognition program created to honor individuals who exhibit courage, leadership, survival, devotion, character and heroism. Candidates are nominated by friends, family and colleagues. Their stories and photos are posted online at www.eaglerarelife.com, where many people vote for their favorite inspirational stories.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7462651-blind-cat-rescue-eagle-rare-award-2015/
This year, parents of nearly 16,000 children in the U.S. will hear the words: “Your child has cancer.” One in five of those children won’t survive. September is Childhood Cancer Awareness Month, and as a leader in the way the world understands, treats and defeats childhood cancer and other life-threatening diseases, St. Jude Children’s Research Hospital® will focus on raising awareness and funds for this very important issue.
Despite significant progress made by St. Jude Children’s Research Hospital, which has helped push the overall childhood cancer survival rates from 20 to more than 80 percent since the hospital opened in 1962, cancer remains the leading cause of death by disease for children over the age of 1. Each year about 175,000 children are diagnosed with cancer worldwide, and 60 percent of these kids don’t have access to modern treatment. For those who win their battles against childhood cancer, victory often comes at a cost as survivors face a much higher risk of experiencing unique long-term health effects later in life.
To view the multimedia release go to:
http://www.multivu.com/players/English/7390851-st-jude-hospital-childhood-cancer-awareness/
The Leukemia & Lymphoma Society (LLS), the world’s leading voluntary non-profit dedicated to blood cancers, released 30 “proof points” - one for each day of September, Blood Cancer Awareness Month - to demonstrate its impact on the cancer landscape and progress towards a world without blood cancers.
LLS has invested more than $1 billion in research to advance breakthrough therapies and cures for blood cancer patients. In many cases, those treatments are now helping patients with other cancers and chronic diseases. Due to its focus on blood cancers, survival rates are improving. Since the early 1960s, five-year survival rates for many blood cancer patients have doubled, tripled and even quadrupled.
To view the multimedia release go to:
http://www.multivu.com/players/English/7554851-lls-blood-cancer-awareness-month/
The European Head and Neck Society (EHNS) and the Make Sense Campaign, today announced the launch of the Third Annual Head and Neck Cancer Awareness week (21–25 September). Through the pan-European Awareness Week, the EHNS and Make Sense Campaign promote education on head and neck cancer risk factors, disease prevention and disease signs and symptoms for both patients and healthcare professionals.
“Each year 350,000 people are diagnosed with head and neck cancer across Europe, and over half will not be alive after five years. However, if diagnosed and treated earlier, patients can have an 80 – 90% survival rate.” said Professor René Leemans, President of the EHNS and Professor and Chief of Otolaryngology – Head and Neck Surgery at VU University Medical Centre. “Through the Make Sense Campaign we are educating people about the early signs of the disease and encouraging them to seek professional help in a timely manner. Additionally, we are advocating for the best possible standards of patient care so that their outcomes can be optimised once they have been diagnosed with the disease.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7628151-support-head-neck-cancer-patients/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Eagle Rare Kentucky Straight Bourbon Whiskey has named Hershel “Woody” Williams of Ona, West Virginia, as the Grand Prize winner of the 2016 Rare Life Award. Eagle Rare will donate $50,000 to Williams’ charity, the Hershel “Woody” Williams Medal of Honor Foundation, and host an awards ceremony in Lexington, Kentucky on February 27, 2016.
The Rare Life Award is an annual recognition program created to honor individuals who exhibit courage, leadership, survival, devotion, character and heroism. Candidates are nominated by friends, family and colleagues. Their stories and photos are posted online at www.eaglerarelife.com.
To view the multimedia release go to:
http://www.multivu.com/players/English/7761951-2016-rare-life-award/
Soy consumption is up 14 percent since 2011,26 yet confusion lingers over soy’s role in everything from human health to food production. To clear up misperceptions, the United Soybean Board (USB) busts five common soy myths with science-backed facts on SoyConnection.com/soy-wisdom.
1) Eating soy does not increase breast cancer risk.
Clinical studies show soy isoflavone exposure does not adversely affect breast tissue as assessed by markers of breast cancer risk, such as breast cell proliferation.1–7 The American Institute for Cancer Research and the American Cancer Society say that women who have been diagnosed with breast cancer can safely consume soyfoods. In fact, the World Cancer Research Fund International has identified a link between soy consumption and an improved survival of breast cancer patients.8-9
“Not only does evidence indicate soyfoods may benefit women with breast cancer, but consuming soy when young helps prevent the onset of this disease later in life27-30,” stated Mark Messina, Ph.D., who has dedicated the past 30 years to understanding the health effects of soyfoods.
To view the multimedia release go to:
http://www.multivu.com/players/English/7877951-united-soybean-board-top-soy-myths/
